Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have had breast cancer treated with surgery that preserved the breast, followed by radiation therapy
• People who are over 18 years old
• People who have developed at least a moderate level (grade 2 or higher) of tissue hardening or fibrosis in the breast area following radiation therapy
• People for whom the radiation treatment planning records from their breast cancer radiotherapy are available
• People whose recent blood test results (taken within 15 days before joining the trial) show that kidney and liver function markers are within acceptable ranges, and — for women aged 70 or older — that a muscle enzyme (CK) level is also within an acceptable range
• Women who could potentially become pregnant must have a negative pregnancy test; women who are post-menopausal or have had certain sterilisation procedures (such as removal of the uterus, fallopian tubes, or tubal occlusion) are not required to meet this condition
• People who have no medical reason preventing them from taking the study drug, pravastatin
• People who have signed and dated a consent form agreeing to participate
• People who are enrolled in the French Social Security system

Who may not be able to join:

• People whose breast cancer has come back (recurred)
• People currently taking any of the following medications: a statin, a fibrate, ciclosporin, systemic fusidic acid, or long-term corticosteroids
• People with a history of muscular dystrophy or any chronic or inherited muscle disease
• People with untreated underactive thyroid (hypothyroidism)
• People whose blood test results show kidney or liver function markers outside the acceptable ranges set by the trial
• Women aged 70 or over whose muscle enzyme (CK) level in blood tests is above the acceptable limit set by the trial
• People who have a known positive test for HIV, hepatitis B, or hepatitis C
• People who are pregnant or breastfeeding
• Women who could potentially become pregnant and are unwilling to use adequate contraception from the start of the trial until four weeks after the last dose of study treatment
• People with a known allergy or sensitivity to pravastatin or any of its ingredients
• People with alcohol misuse issues
• People who have taken part in another clinical drug trial within the past 30 days
• People whose legal, physical, psychological, or mental status would prevent them from signing the consent form or completing the trial

Important: Always verify eligibility with the trial site directly before applying.